Professor Guosheng Ren: Highlighting the French-Chinese Breast Cancer Forum, New Technologies Lead Developments in Breast-Conserving Surgery | 2024 SFBCS

Professor Guosheng Ren: Highlighting the French-Chinese Breast Cancer Forum, New Technologies Lead Developments in Breast-Conserving Surgery | 2024 SFBCS

In the vibrant spring of April in Chongqing, from April 19 to April 20, 2024, the "11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS)" was held, co-hosted by several prestigious institutions including the Chinese Anti-Cancer Association's Breast Cancer Committee, the Breast Surgery Expert Group of the Chinese Medical Doctor Association, the Oncology Clinical Research Management Committee of the Chinese Anti-Cancer Association, the Chongqing Clinical Medical Research Federation, the Breast and Thyroid Surgery Department of the First Hospital of Chongqing Medical University, the French Academy of Medical Sciences, and the French Surgical Academy Foundation. Experts from China and abroad gathered to share and exchange knowledge on basic breast cancer research, pathology diagnosis, surgical procedures, and systemic treatment, guiding new directions in the precision medicine era for breast cancer diagnosis and treatment. During the conference, "Oncology Frontier" had the privilege of interviewing Professor Guosheng Ren, the chairman of the conference, who shared insights on the highlights of the forum and the advancements in breast-conserving and reconstructive surgery.
Professor Yongsheng Wang: Precision Decision-Making in Sentinel Lymph Node Biopsy—Selecting the Right Patient Population, Diagnosis, and Clinical Management | 2024 SFBCS

Professor Yongsheng Wang: Precision Decision-Making in Sentinel Lymph Node Biopsy—Selecting the Right Patient Population, Diagnosis, and Clinical Management | 2024 SFBCS

The 11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS) was held in Chongqing on April 19-20, 2024. Experts from around the world shared their knowledge on basic breast cancer research, pathology diagnosis, surgical procedures, and systemic treatment. In the surgical forefront segment, Professor Yongsheng Wang from Shandong Cancer Hospital presented on "Precision Decision-Making in Sentinel Lymph Node Biopsy," discussing clinical practice decisions and patient benefits related to breast cancer sentinel lymph node biopsy (SLNB). "Oncology Frontier" interviewed Professor Wang at the conference, providing insights into the precise selection of patients for SLNB, diagnosis, and clinical management.
Professor Jun Ma : Continuous Innovation in Drugs Powers the Transition of Cancer into Chronic Disease Management

Professor Jun Ma : Continuous Innovation in Drugs Powers the Transition of Cancer into Chronic Disease Management

For cancer patients, prolonged drug therapy, particularly intravenous treatments, can lead to various inconveniences like infusion reactions and phlebitis. The emergence of new formulations of anticancer drugs not only reduces treatment costs and saves time but also brings convenience to both patients and clinicians. In an era where chronic disease management is becoming more prevalent, how will these new formulations be implemented to help cancer patients move towards recovery? "Oncology Frontier" has invited Professor Jun Ma  from the Harbin Institute of Hematology and Oncology to discuss these issues.
EBMT China Voice | Dr. Yishan Ye : Comparative Study of Haploidentical, Sibling Matched, and Unrelated Matched Allogeneic Hematopoietic Stem Cell Transplantation in Core Binding Factor AML Patients in Second Complete Remission (CR2)

EBMT China Voice | Dr. Yishan Ye : Comparative Study of Haploidentical, Sibling Matched, and Unrelated Matched Allogeneic Hematopoietic Stem Cell Transplantation in Core Binding Factor AML Patients in Second Complete Remission (CR2)

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a crucial therapeutic option for a variety of benign and malignant hematological diseases. In recent years, the proportion of haploidentical transplants has been increasing due to advancements in the technology. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was held in Glasgow, UK. The conference focused on the latest developments in stem cell transplantation and cellular therapy, pushing forward better clinical prognoses for hematologic patients. At this EBMT Annual Meeting, Professor Huang He's team from the First Affiliated Hospital of Zhejiang University School of Medicine was selected for one invited report, five oral presentations, and fifteen posters. "Oncology Outlook - Hematology News" invited Dr. Yishan Ye  from The First Affiliated Hospital of Zhejiang University School of Medicine to share insights and progress from his oral presentation on the study comparing haploidentical allo-HSCT with related/unrelated matched transplants, which potentially shows better prognostic outcomes.
Professor Xinan Sheng’s Insights on Key Studies in Kidney Cancer at the 2024 ASCO-GU Annual Meeting | ASCO-GU Highlights Reviewed by Key Opinion Leaders

Professor Xinan Sheng’s Insights on Key Studies in Kidney Cancer at the 2024 ASCO-GU Annual Meeting | ASCO-GU Highlights Reviewed by Key Opinion Leaders

The 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) was held from January 25th to 27th in San Francisco, showcasing the most innovative scientific advancements in the field and discussing future treatment directions for genitourinary cancers. Among them, several groundbreaking studies in the field of kidney cancer were presented, and "Oncology Frontier" invited Professor Xinan Sheng and Professor Xieqiao Yan from Peking University Cancer Hospital to interpret these studies for readers.
Professor Ning Shen’s Team: Mechanism of Resistance to Cefiderocol in Highly Virulent Klebsiella pneumoniae | ESCMID Global 2024

Professor Ning Shen’s Team: Mechanism of Resistance to Cefiderocol in Highly Virulent Klebsiella pneumoniae | ESCMID Global 2024

As the global issue of antimicrobial resistance intensifies, newly emerging resistant bacterial strains pose a significant threat to public health. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Ning Shen's team from Peking University Third Hospital (Abstract No.: E0451) focused on the resistance issues of cefiderocol, a drug not yet marketed in China. The study identified that cefiderocol can induce resistance and amplification of the blaSHV-12 gene in vitro. Long-read sequencing technology demonstrated its potential for rapid and accurate detection of resistance gene amplification, offering a new tool for future resistance research.
ASCO GU Researcher Speaks丨Professor St-Laurent: Urinary Tumor DNA Detects Minimal Residual Disease, Aiding in Extended Patient Survival

ASCO GU Researcher Speaks丨Professor St-Laurent: Urinary Tumor DNA Detects Minimal Residual Disease, Aiding in Extended Patient Survival

The ASCO-GU 2024, a major event in the field of urologic oncology, was held in San Francisco, USA, showcasing numerous innovative research advancements and discussing future treatment directions for urologic and male reproductive system tumors. For patients with non-muscle invasive bladder cancer (NMIBC) who do not respond to Bacillus Calmette-Guérin (BCG) treatment, there remains a need to find effective tools to detect the risk of recurrence or progression after second-line bladder-sparing treatments. During the conference, Professor Marie-Pier St-Laurent from the University of British Columbia presented the latest advancements in using whole-genome analysis of urinary tumor DNA (utDNA) to identify minimal residual disease (MRD) and quantify genomic changes, sharing in-depth insights in an interview with Oncology Frontier.
EBMT China Voice | Professor Yue Lu ‘s Team: Clinical Characteristics and Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation Combined with Mucormycosis

EBMT China Voice | Professor Yue Lu ‘s Team: Clinical Characteristics and Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation Combined with Mucormycosis

Mucormycosis is a group of rare and highly invasive fungal diseases, and its combination with allogeneic hematopoietic stem cell transplantation increases the difficulty of diagnosis and treatment. Previously, the difficulty in rapidly diagnosing mucormycosis often led to poor prognosis in patients with transplantation-associated mucormycosis. At the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Dr. Xu Fang from Professor Yue Lu 's team at Hebei Yanda Lu Daopei Hospital reported a recent clinical study that analyzed the characteristics and prognostic factors of patients with allogeneic hematopoietic stem cell transplantation combined with mucormycosis.
EBMT Hot Commentary | Professor Jie Jin: Turning the Tide, Extending Survival — Pre-Transplant Salvage Chemotherapy for Relapsed/Refractory AML Based on Venetoclax

EBMT Hot Commentary | Professor Jie Jin: Turning the Tide, Extending Survival — Pre-Transplant Salvage Chemotherapy for Relapsed/Refractory AML Based on Venetoclax

Acute myeloid leukemia (AML) is a common and aggressive hematological malignancy with poor prognosis. For patients with relapsed/refractory (R/R) AML, allogeneic hematopoietic stem cell transplantation (allo-SCT) is one of the important treatment options. However, patients with R/R AML often face primary or secondary drug resistance and limited treatment options due to complications and physical condition, resulting in low re-induction remission rates. Therefore, selecting the appropriate chemotherapy regimen before transplantation to achieve deeper remission and secure better timing for transplantation, thereby optimizing the outcome of allo-SCT and extending patient survival, is a critical clinical issue. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was held in Glasgow, UK, focusing on the latest advances in stem cell transplantation and cellular therapy, and pushing forward better clinical outcomes for patients with hematological diseases and malignancies. In this issue, we are pleased to have Professor Jie Jin share her insights on the latest research in pre-transplant chemotherapy for patients with relapsed/refractory AML.
Relapsed and refractory AML is a very difficult clinical problem, and there is currently no unified and efficient treatment plan.

Relapsed and refractory AML is a very difficult clinical problem, and there is currently no unified and efficient treatment plan.

Relapsed and refractory acute myeloid leukemia (AML) presents one of the most formidable challenges in oncology, lacking a unified and efficient treatment strategy. Dr. Johannes Schetelig, Head of the Cell Therapy Unit at the Technical University of Dresden and Chair of the Clinical Trials Unit within the DKMS, offers invaluable insights into the complexities and evolving approaches in managing this condition. From the nuances of defining refractory AML at various stages to the critical decision-making involved in stem cell transplantation, Dr. Schetelig's expertise sheds light on current practices and future directions. This article delves into the multifaceted strategies for treating relapsed and refractory AML, focusing on patient suitability for stem cell transplantation, predictive clinical characteristics for better outcomes, and proactive measures to prevent relapse post-transplantation.